Evidence map›Paper›PMID 33919938›Full record

ArticleTropical medicine and infectious disease2021

Comparative Yield of Tuberculosis during Active Case Finding Using GeneXpert or Smear Microscopy for Diagnostic Testing in Nepal: A Cross-Sectional Study.

Suman Chandra Gurung, Kritika Dixit, Bhola Rai, Raghu Dhital, Puskar Raj Paudel, Shraddha Acharya, Gangaram Budhathoki, Deepak Malla, Jens W Levy, Knut Lönnroth and 8 more

Open access · goldAbstract read
In one paragraph

Article in Tropical medicine and infectious disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 4 countries.

Suman Chandra GurungBirat Nepal Medical Trust, Kathmandu 44600, Nepal.ORCID 0000-0002-4012-7562
Kritika DixitBirat Nepal Medical Trust, Kathmandu 44600, Nepal.
Bhola RaiBirat Nepal Medical Trust, Kathmandu 44600, Nepal.
Raghu DhitalBirat Nepal Medical Trust, Kathmandu 44600, Nepal.
Puskar Raj PaudelBirat Nepal Medical Trust, Kathmandu 44600, Nepal.
Shraddha AcharyaBirat Nepal Medical Trust, Kathmandu 44600, Nepal.
Gangaram BudhathokiBirat Nepal Medical Trust, Kathmandu 44600, Nepal.
Deepak MallaBirat Nepal Medical Trust, Kathmandu 44600, Nepal.
Jens W LevyKNCV Tuberculosis Foundation, 2514 JD The Hague, The Netherlands.
Knut LönnrothDepartment of Global Public Health, WHO Collaborating Center on Tuberculosis and Social Medicine, Karolinska Institutet, 10653 Stockholm, Sweden.
Andrew RamsaySchool of Medicine, University of St Andrews, St Andrews KY16 9TF, UK.
Buddha BasnyatOxford University Clinical Research Unit, Kathmandu 44600, Nepal.
Anil ThapaNational Tuberculosis Centre, Kathmandu 44600, Nepal.
Gokul MishraBirat Nepal Medical Trust, Kathmandu 44600, Nepal.
Bishal SubediHealth Office, Pyuthan 22300, Nepal.
Mohammad Kashim ShahNick Simons Institute, Lalitpur 44600, Nepal.
Anil ShresthaNick Simons Institute, Lalitpur 44600, Nepal.
Maxine CawsBirat Nepal Medical Trust, Kathmandu 44600, Nepal.
Nepal Medical College Teaching Hospital · NPNick Simons Institute · NPKarolinska Institutet · SEKathmandu University · NPNLR Nepal · NPTuBerculosis Vaccine Initiative · NLUniversity of St Andrews · GB

Funding

Horizon 2020 733174Stop TB Partnership 5-31
6 · The paper itself

Abstract

This study compared the yield of tuberculosis (TB) active case finding (ACF) interventions applied under TB REACH funding. Between June 2017 to November 2018, Birat Nepal Medical Trust identified presumptive cases using simple verbal screening from three interventions: door-to-door screening of social contacts of known index cases, TB camps in remote areas, and screening for hospital out-patient department (OPD) attendees. Symptomatic individuals were then tested using smear microscopy or GeneXpert MTB/RIF as first diagnostic test. Yield rates were compared for each intervention and diagnostic method. We evaluated additional cases notified from ACF interventions by comparing case notifications of the intervention and control districts using standard TB REACH methodology. The project identified 1092 TB cases. The highest yield was obtained from OPD screening at hospitals (n = 566/1092; 52%). The proportion of positive tests using GeneXpert (5.5%, n = 859/15,637) was significantly higher than from microscopy testing 2% (n = 120/6309). (OR = 1.4; 95%CI = 1.12-1.72; p = 0.0026). The project achieved 29% additionality in case notifications in the intervention districts demonstrating that GeneXpert achieved substantially higher case-finding yields. Therefore, to increase national case notification for TB, Nepal should integrate OPD screening using GeneXpert testing in every district hospital and scale up of community-based ACF of TB patient contacts nationally.

Indexed as

ACF interventionsACF strategiesactive case findingGeneXpertNepalTB yield rate

Identifiers

PMID33919938
PMCPMC8167510
OpenAlexW3155312117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.